Abstract

Compounding for the Treatment of COVID-19 and Long COVID, Part 5: Associated Conditions, Prophylaxis, and Effective Treatment

Author(s): Riepl Mike, Kaiser Joe

Issue: Sep/Oct 2023 - Volume 27, Number 5

Page(s): 368-380

Download in electronic PDF format for $75

Abstract

The effects of infection with the highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the coronavirus- disease–2019 (COVID-19) it engenders continue to demonstrate that worldwide, the detection, prediction, and control of novel-pathogen pandemics remain largely unattained achievements. Key to successfully meeting those goals is a thorough understanding of the mechanisms of evolving causative agents and effective prophylaxis against them. In this article, we review common conditions that afflict people with COVID-19 or long COVID, examine the effectiveness of vaccines designed to prevent infection with SARS-CoV-2 and mitigate its sequelae, and provide formulations for 2 compounded preparations that can assist recovery from acute and chronic conditions caused by that virus when manufactured drugs are unavailable in required dosages or dosage forms or cannot be tolerated by the patient.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Sep/Oct 2023 Pg. 368-380	Compounding for the Treatment of COVID-19 and Long COVID, Part 5: Associated Conditions, Prophylaxis, and Effective Treatment Author(s): Riepl Mike, Kaiser Joe
Jan/Feb 2023 Pg. 12-21	Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants Author(s): Riepl Mike
May/Jun 2023 Pg. 192-200	Compounding for the Treatment of COVID-19 and Long COVID, Part 3: The Role of Toll-like Receptors in SARS-CoV-2 Infection and COVID Development Author(s): Riepl Mike, Kaiser Joe
Jul/Aug 2023 Pg. 284-293	Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Author(s): Riepl Mike, Kaiser Joe
Mar/Apr 2023 Pg. 98-107	Compounding for the Treatment of COVID-19 and Long COVID, Part 2: Manifestations of Infection, Nomenclature, Transmission, and Treatment Author(s): Riepl Mike
Jul/Aug 2020 Pg. 287-295	Pharmacies on the Frontline: Responding to the COVID-19 Pandemic Author(s): McElhiney Linda F
Jul/Aug 2020 Pg. 268	PreScription: COVID-19 and Compounding Pharmacists Author(s): Allen Loyd V Jr
Sep/Oct 2020 Pg. 358-364	Cocamidopropyl Betaine Surfactant 0.075% Solution in Physiological Serum for Hygiene Process of COVID-19 Intubated Patients Author(s): Nogales Luis Marcos, Jiménez Labaig Luis, Abarca Lachén Edgar, Gil Melcón María, López-Nieves Marisol
Jul/Aug 2003 Pg. 288-291	Basics of Compounding for Raynaud's Disease Author(s): Glasnapp Andrew
May/Jun 2003 Pg. 170-174	Five Compounds for Treating Diabetes-Related Conditions Author(s): Meece Jerry
Jan/Feb 2003 Pg. 10-15 View Sample	Compounding for the Effects of Weapons of Mass Destruction Author(s): Sammarco Domenic A
Jul/Aug 2003 Pg. 266-270	Sensitization Therapy for Warts Author(s): Kuntz Rachael
Mar/Apr 2021 Pg. 109-113	Descriptive Report of Individual State Responses to Personal Protective Equipment Shortages for Pharmacy Practice During the Covid-10 Pandemic Author(s): Roberts Patricia A, Eberwein Samuel M, Youmans Danielle, Amerine Lindsey B
May/Jun 2003 Pg. 188-191	Treating Canine Hepatic Disease Author(s): Davidson Gigi S
Jul/Aug 2020 Pg. 316	Hydroxychloroquine Sulfate 25 mg/mL in Ora-Plus:Ora-Sweet SF Author(s): Allen Loyd V Jr
Jul/Aug 2021 Pg. 268	PreScription: Endemics, Epidemics, and Pandemics Author(s): Allen Loyd V Jr
Jul/Aug 2020 Pg. 310	Calculations Author(s): Stockton Shelly J
Nov/Dec 2003 Pg. 460-463 View Sample	Basics of Compounding for Dry-Skin Conditions Author(s): Allen Loyd V Jr
Sep/Oct 2000 Pg. 349	Probiotics and Their Effect on Leaky Gut Syndrome and Associated Diseases Author(s): Hinze John, Mahan Tracy
Jul/Aug 2021 Pg. 296-297	A Permanent Path for Urgent-use Compounding? APC-supported Legislation Would Allow 503As to Fill Gaps in Coverage When 503Bs Cannot Author(s): Brunner Scott